These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15646365)

  • 21. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy.
    Berger W; Abelson MB; Gomes PJ; Beck M; Kimura S; Westbrook T; Storms W; Galant S
    Ann Allergy Asthma Immunol; 2005 Oct; 95(4):361-71. PubMed ID: 16279567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A multicenter, double-masked, randomized evaluation of olopatadine 0.2% using the conjunctival allergen challenge model in Japanese patients with allergic conjunctivitis].
    Ohno S;
    Nippon Ganka Gakkai Zasshi; 2012 Dec; 116(12):1123-9. PubMed ID: 23379201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
    Leonardi A; Quintieri L
    Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of olopatadine hydrochloride, an anti-histamine drug, on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats.
    Tamura T; Komai M
    Int Immunopharmacol; 2008 Jun; 8(6):916-21. PubMed ID: 18442798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacological profile and clinical efficacy of olopatadine hydrochloride ophthalmic solution (Patanol 0.1% ophthalmic solution)].
    Watanabe M; Kodama H; Hasegawa K; Itoh K
    Nihon Yakurigaku Zasshi; 2007 Sep; 130(3):221-31. PubMed ID: 17878619
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug approvals: '08 in review. Olopatadine hydrochloride (Patanase) nasal spray.
    Laustsen G; Carrillo F; Johnson J; Smith C
    Nurse Pract; 2009 Feb; 34(2):29. PubMed ID: 19155880
    [No Abstract]   [Full Text] [Related]  

  • 27. Rupatadine in allergic rhinitis and chronic urticaria.
    Mullol J; Bousquet J; Bachert C; Canonica WG; Gimenez-Arnau A; Kowalski ML; Martí-Guadaño E; Maurer M; Picado C; Scadding G; Van Cauwenberge P
    Allergy; 2008 Apr; 63 Suppl 87():5-28. PubMed ID: 18339040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
    Abelson MB; Spitalny L
    Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.
    Meltzer EO; Hampel FC; Ratner PH; Bernstein DI; Larsen LV; Berger WE; Finn AF; Marple BF; Roland PS; Wall GM; Brubaker MJ; Dimas C; Potts SL; Silver LH; Barnes JR
    Ann Allergy Asthma Immunol; 2005 Dec; 95(6):600-6. PubMed ID: 16400902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Olopatadine].
    Taéron C
    Rev Infirm; 2004 Apr; (100):43-4. PubMed ID: 15222186
    [No Abstract]   [Full Text] [Related]  

  • 31. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
    Rosenwasser LJ; O'Brien T; Weyne J
    Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar.
    Ratner PH; Hampel FC; Amar NJ; van Bavel JH; Mohar D; Marple BF; Roland PS; Wall GM; Brubaker MJ; Drake M; Turner D; Silver LH
    Ann Allergy Asthma Immunol; 2005 Nov; 95(5):474-9. PubMed ID: 16312171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
    Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
    Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.
    Shah SR; Nayak A; Ratner P; Roland P; Michael Wall G
    Clin Ther; 2009 Jan; 31(1):99-107. PubMed ID: 19243710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older.
    Roland PS; Ryan MW; Wall GM
    Expert Opin Pharmacother; 2010 Jun; 11(9):1559-67. PubMed ID: 20482305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azelastine and olopatadine in the treatment of allergic rhinitis.
    Kaliner MA
    Ann Allergy Asthma Immunol; 2009 Nov; 103(5):373-80. PubMed ID: 19927534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. H1-antihistamines in the elderly.
    Kaliner MA
    Clin Allergy Immunol; 2002; 17():465-81. PubMed ID: 12113227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis].
    Endre L; Hidasi V
    Orv Hetil; 2006 Sep; 147(36):1741-3. PubMed ID: 17087018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils.
    Fukuishi N; Matsuhisa M; Shimono T; Murata N; Iwanaga M; Sagara H; Matsui N; Akagi M
    Jpn J Pharmacol; 2002 Apr; 88(4):463-6. PubMed ID: 12046991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.